Lipid nanocapsules as a versatile platform for drug delivery

Taher Hatahet, Siyang Wu, Hong Yang, Wafa Al-Jamal

Research output: Contribution to conferencePaper

Abstract

Lipid nanocapsules (LNCs) have shown promising results in terms of lipophilic drug loading with interesting features related to the simplicity of the preparation method, scalability, and commercial availability of its components. However, due to small size of these particles, high surfactant (Kolliphor HS15) concentration is required to maintain their stability, where this surfactant is a major cause of LNCs in vitro cellular toxicity. In the work, modifications to the composition of LNCs were made to the surfactant and oily core to widen the formulation excipients selection boosting its compatibility with different drug candidates. At a later stage, modified LNCs were tested for their toxicity on CT26 cells to showcase that such modification can improve LNCs safety in cells. This work opens the door for further research on how LNCs can become a safe and effective drug delivery system for topical and parenteral application.
Original languageEnglish
Publication statusPublished - 7 Sept 2022
Externally publishedYes

Keywords

  • Lipid nanocapsules
  • CT26
  • In vitro cellular toxicity
  • formulation optimization

Fingerprint

Dive into the research topics of 'Lipid nanocapsules as a versatile platform for drug delivery'. Together they form a unique fingerprint.

Cite this